Clinical Trial Update: Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating fluciclovine PET imaging to detect biochemical recurrence of prostate cancer in patients who have a negative PSMA PET. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Axumin (fluciclovine F-18)

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Prostate Cancer | Phase 4 | Status: ACTIVE_NOT_RECRUITING